Evommune raises $50M to fund clinical trials in skin diseases
Evommune has raised a $50 million funding round that it plans to use to bankroll a series of clinical trials over the next two years for skin diseases, a bet that the executive team can replicate the success they had at their past companies that were sold to Big Pharma buyers.
The company has a Phase IIa trial of its experimental drug EVO101, which targets IRAK4, in atopic dermatitis. The drug was licensed from Eli Lilly after the drugmaker made a deal for Dermira in 2020. The nearly 120-patient trial of the drug is slated to read out this summer, CEO and co-founder Luis Peña told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.